2018 Competition Side effects 
pharmaphorum
JULY 11, 2022
The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6
European Pharmaceutical Review
DECEMBER 14, 2023
Observational studies should not be seen as competition to RCTs but as complementary to them, and as a sector we need to stop working in silos and develop an integrated and more comprehensive approach to evidence-based decision-making in safeguarding public health. 2018; 8(1). EMA/95098/2010.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 22, 2023
In 2022, the FDA approved only 37 new medicines, an underwhelming number compared to 98 in 2018. However, while only around 34% of the approvals in 2018 were for orphan drugs, 54% new approvals in 2022 were for drugs to treat rare diseases. rises/second (SD 0.0628) in the placebo group.
Pharmaceutical Technology
MAY 31, 2023
The document would include the drug/biological product name, side effects, directions for use, safety information, and a concise summary of indications and uses. According to a 2018 study , nonadherence is especially an issue in the case of chronic illness where patients may be expected to take medications at least once daily.
Pharmaceutical Technology
MARCH 24, 2023
Fox says adjuvant protein subunit vaccines can be a safer approach compared to live attenuated virus vaccines as there is a minimized risk of developing side effects. Results from the Phase II trial were released for the vaccine in September 2018.
Pharmaceutical Technology
NOVEMBER 30, 2022
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The same can be said for the US. of adults were overweight, 42.4%
Pharmaceutical Technology
NOVEMBER 30, 2022
A 2017–2018 National Health and Nutrition Examination Survey (NHANES), showed that 30.7% In the past, obesity medications were often dismissed due to insufficient efficacy data and the fact that they were associated with a high occurrence of side effects. The same can be said for the US. of adults were overweight, 42.4%
Expert insights. Personalized for you.
52 
Let's personalize your content